# Alwide Plus China Post-market Clinical Investigation

> **NCT07304427** · — · COMPLETED · sponsor: **Shanghai MicroPort CardioFlow Medtech Co., Ltd.** · enrollment: 75 (actual)

## Conditions studied

- Severe Aortic Stenosis
- Transcatheter Aortic Valve Replacemen

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07304427
- **Lead sponsor:** Shanghai MicroPort CardioFlow Medtech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-03
- **Primary completion:** 2025-10-11
- **Final completion:** 2025-11-04
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07304427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07304427, "Alwide Plus China Post-market Clinical Investigation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07304427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*